SCHEMBL6548227

SCHEMBL6548227

CCCCOC(C=O)CC(=O)NC(CC(O)c1ccccc1)N1CCOCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
GAA P10253 2/20 0.45
TSHR P16473 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 4/20 0.42
TP53 P04637 4/20 0.42
MEN1 O00255 3/20 0.42
MAPT P10636 2/20 0.42
THRB P10828 1/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
NFKB1 P19838 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
UGCG Q16739 1/20 0.41
MTOR P42345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549347 0.82 MEN1 (0.43) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6549071 0.81 KMT2A (0.41) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6550110 0.79 KMT2A (0.41) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6548271 0.79 KMT2A (0.45) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6549283 0.77 SMN1; SMN2 (0.45) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6549353 0.73 MEN1 (0.44) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6547904 0.72 MEN1 (0.48) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6548444 0.72 POLB (0.47) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6549109 0.70 LMNA (0.44) LMNASMN1; SMN2GAATSHRALDH1A1
SCHEMBL6547253 0.66 KMT2A (0.44) LMNASMN1; SMN2TSHRALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1106609-B1 Aminoalcohol derivative and medicament comprising the same SEIKAGAKU KOGYO CO LTD (JP) 2004-12-01 EP disclosed
US-6407064-B2 A MORPHOLINO RING CONTAINING ALKYLAMINOALCOHOL DERIVATIVE OR SALTS USEFUL FOR TREATING NEURONAL DISEASES AND AN AGENT FOR PROTECTING BRAIN SEIKAGAKU CORPORATION (JP) 2002-06-18 US disclosed
US-20010003741-A1 Aminoalcohol derivative and medicament comprising the same SEIKAGAKU CORPORATION (JP) 2001-06-14 US disclosed
EP-1106609-A2 Aminoalcohol derivative and medicament comprising the same SEIKAGAKU CORPORATION (JP) 2001-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003741-A1 Aminoalcohol derivative and medicament comprising the same SGMS2, FABP7, SGMS1 LMNA 682/4885SMN1; SMN2 41/4885GAA 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.